Abstract Details

Title Effects of age, sex, and concussion history on pattern reversal visual evoked potentials in children

Topic Child Neurology and Developmental Neurology

Presentation(s) Child Neurology and Developmental Neurology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 013

Objective To characterize effects of age, sex, and concussion history on pattern reversal visual evoked potentials (prVEP) in children.

Background prVEP peak time and amplitude metrics have been used widely to probe the visual system in neurologic conditions. While informative, peak metrics provide an incomplete measurement of data variance. Principal component analysis (PCA) can more fully characterize prVEP variation. Variability across sex and age may be modeled and adjusted for, which can account for potentially confounding developmental changes in children.

Design/Methods prVEP was recorded during two sessions separated by 2 months (on average) on 155 healthy subjects ages 11-19 years with the Diopsys NOVA^TM system. A PCA model retaining principal components (PCs) that described >95% of the variability was generated from 40 randomly selected “training” subjects (50% female). To determine the model’s generalizability, we compared the distribution of modeled PC coefficients from training subjects and 40 age- and sex-matched “test” subjects. PC coefficients were derived from each session for each test subject to examine intra-subject reliability. We explored the effects of age, sex, and remote concussion history on PC coefficients.

Results Seven PCs accounted for >95% of the variability. The model was generalizable (training vs. test distribution of coefficients p>0.5 for all PCs) with good within-subject reliability (R>0.75 for all PCs). Female/male comparison revealed differences in two PCs (Cohen d effect size: PC1 0.31, PC4 -0.39; p<0.05). PC2 and PC5 showed a significant correlation with age (PC2 R=-0.32, PC5 R=0.17; p<0.05). Post-hoc comparison of age- and sex-adjusted coefficients revealed a significant effect size of remote concussion history for two PCs (Cohen d PC1: 0.58, PC3: -0.42; p<0.05).

Conclusions PCA offers a generalizable, reliable, and unbiased approach to pediatric prVEP, addressing variation with age and sex. We found prVEP differences that suggest asymptomatic subjects with a remote concussion history should be excluded from pediatric normative datasets.

Authors/Disclosures
Carlyn Patterson Gentile, MD PRESENTER	The institution of Dr. Patterson Gentile has received research support from NIH/NINDS. The institution of Dr. Patterson Gentile has received research support from Children's Hospital of Philadelphia. Dr. Patterson Gentile has received personal compensation in the range of $500-$4,999 for serving as a Faculty, Annual Scientific Meeting, Scottsdale Meeting with American Headache Society. Dr. Patterson Gentile has received personal compensation in the range of $5,000-$9,999 for serving as a Early Career Awardee with American Headache Society. Dr. Patterson Gentile has received personal compensation in the range of $0-$499 for serving as a Research Prize Awardee and travel expense coverage with NIH Pain Consortium. Dr. Patterson Gentile has received personal compensation in the range of $500-$4,999 for serving as a Faculty, Speaker with Headache Cooperative of New England. Dr. Patterson Gentile has received personal compensation in the range of $500-$4,999 for serving as a Speaker, Awardee with �鶹��ýӳ��.
	No disclosure on file
	No disclosure on file
Kristy Arbogast	The institution of Kristy Arbogast has received research support from NIH. The institution of Kristy Arbogast has received research support from Pennsylvania Department of Health. The institution of Kristy Arbogast has received research support from Football Research Inc.
Christina Master, MD, FAAP, CAQSM (Children's Hospital of Philadelphia)	The institution of Dr. Master has received research support from NIH. The institution of Dr. Master has received research support from DoD. The institution of Dr. Master has received research support from AMSSM. The institution of Dr. Master has received research support from PA Department of Health. Dr. Master has received intellectual property interests from a discovery or technology relating to health care. Dr. Master has received intellectual property interests from a discovery or technology relating to health care. Dr. Master has received intellectual property interests from a discovery or technology relating to health care.
Geoffrey K. Aguirre, MD, PhD (University of Pennsylvania, Department of Neurology)	Dr. Aguirre has received stock or an ownership interest from Nia therapeutics. The institution of Dr. Aguirre has received research support from Lion's Foundation. The institution of Dr. Aguirre has received research support from National Institutes of Health. The institution of Dr. Aguirre has received research support from Johnson and Johnson. The institution of Dr. Aguirre has received research support from Department of Defense.

�鶹��ýӳ��

�鶹��ýӳ��